Wirth LJ, et al. - Given the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial reported hypertension (HTN) as the most frequent adverse event of lenvatinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR)1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and stem cell factor receptor (KIT), researchers performed this exploratory analysis to examine treatment-emergent hypertension (TE-HTN) and its association with lenvatinib efficacy and safety in SELECT. They found that monitoring and management of HTN was required as it was identified to be a clinically significant adverse event. In patients with radioiodine-refractory differentiated thyroid cancer, a significant correlation of TE-HTN with improved outcomes was observed, indicating that HTN may be predictive for lenvatinib efficacy in this population.